Biotherapeutic antibody generation produces many lead candidates, and translational scientists must make informed decisions during candidate selection to reduce the risk of complications and failure during development. To characterize antibody-antigen and antibody-FCγ-receptor interactions, they commonly employ surface plasmon resonance (SPR). In addition to analyzing affinity and specificity, SPR provides scientists with valuable insights into the likelihood of developing an antibody candidate into a safe, stable, and effective drug, which ensures a smooth journey from the benchtop to the clinic.
Download this whitepaper from Cytiva to learn how their advanced SPR systems
- Enhance the drug discovery process
- Support informed decision making during lead candidate selection
- Reduce the risk of complications and failure during development
- Leverage technology to deliver valuable insights into a candidate’s suitability for development
